Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2024.02.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Warfarin reduces circulating white blood cell count: Post-hoc analysis of two randomized trials.
Thromb Res
September 2025
Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Electronic address:
Warfarin is a widely used vitamin K antagonist (VKA) with known pleiotropic effects beyond anticoagulation. Preclinical and case-control evidence suggests that warfarin may affect hematopoiesis, but longitudinal human evidence is lacking. To explore this potential effect, we conducted a post-hoc analysis of participants in the Hokusai-VTE and ENGAGE AF-TIMI 48 trials, which randomized patients to warfarin or the direct oral anticoagulant edoxaban with routine laboratory testing at predefined follow-up visits.
View Article and Find Full Text PDFNutritional and Pharmacological Significance of Pomegranate (Punica granatum L): A Comprehensive Narrative Review.
Nutr Rev
September 2025
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Pomegranate (Punica granatum L) is a rich source of bioactive compounds, including punicalagin, ellagic acid, anthocyanins, and urolithins, which contribute to its broad pharmacological potential. This review summarizes evidence from in vitro and in vivo experiments, as well as clinical studies, highlighting pomegranate's therapeutic effects in inflammation, metabolic disorders, cancer, cardiovascular disease, neurodegeneration, microbial infections, and skin conditions. Mechanistic insights show modulation of pathways such as nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK), alpha serine/threonine-protein kinase (AKT1), and nuclear factor erythroid 2-related factor 2 (Nrf2).
View Article and Find Full Text PDFGenomic resequencing unravels species differentiation and polyploid origins in the aquatic plant genus Trapa.
Plant J
September 2025
State Key Laboratory of Plant Diversity and Specialty Crops, Wuhan Botanical Garden, Chinese Academy of Science, Wuhan, Hubei, 430074, China.
Trapa L. is a non-cereal aquatic crop with significant economic and ecological value. However, debates over its classification have caused uncertainties in species differentiation and the mechanisms of polyploid speciation.
View Article and Find Full Text PDFA Novel CART-Driven Decision Tree Combining NLR and CRP for Early Prognostication of Severe Acute Pancreatitis: A Prospective Vietnamese Cohort Study.
Clin Transl Gastroenterol
September 2025
Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Cho Minh City, Vietnam.
Background: Severe acute pancreatitis (SAP) is a life-threatening condition requiring early risk stratification. While the Bedside Index for Severity in Acute Pancreatitis (BISAP) is widely used, its reliance on complex parameters limits its applicability in resource-constrained settings. This study introduces a decision tree model based on Classification and Regression Tree (CART) analysis, utilizing Neutrophil-to-Lymphocyte Ratio (NLR) and C-reactive Protein (CRP), as a simpler alternative for early SAP prediction.
View Article and Find Full Text PDFProtocol for a core outcome set for pharmacological treatments in hospitalised patients with acute viral respiratory infections (COSAVRI).
PLoS One
September 2025
Centre for Experimental Pathogen Host Research, School of Medicine, University College Dublin, Dublin, Ireland.
Background: Acute viral respiratory infections (AVRIs) rank among the most common causes of hospitalisation worldwide, imposing significant healthcare burdens and driving the development of pharmacological treatments. However, inconsistent outcome reporting across clinical trials limits evidence synthesis and its translation into clinical practice. A core outcome set (COS) for pharmacological treatments in hospitalised adults with AVRIs is essential to standardise trial outcomes and improve research comparability.
View Article and Find Full Text PDF